Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload

Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload

Protein S-nitrosylation (SNO) is a post-translational modification of protein thiol, which is a major effector mechanism of nitric oxide (NO) signaling. Level of protein SNO is controlled by S-nitrosoglutathione reductase (GSNOR). Recently, we showed that GSNOR mitigates intracellular calcium overlo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A19210-A19210
Hauptverfasser: Mori, Naohiro, Kai, Shinichi, Sips, Patrick, Irie, Tomoya, Ichinose, Fumito
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A19210
container_issue Suppl_1 Suppl 1
container_start_page A19210
container_title Circulation (New York, N.Y.)
container_volume 134
creator Mori, Naohiro
Kai, Shinichi
Sips, Patrick
Irie, Tomoya
Ichinose, Fumito
description Protein S-nitrosylation (SNO) is a post-translational modification of protein thiol, which is a major effector mechanism of nitric oxide (NO) signaling. Level of protein SNO is controlled by S-nitrosoglutathione reductase (GSNOR). Recently, we showed that GSNOR mitigates intracellular calcium overload and LV remodeling and dysfunction induced by chronic β-adrenergic receptor (AR) stimulation. To further explore the role of protein SNO in LV remodeling and heart failure, we examined impact of chronic pressure overload induced by transverse aortic constriction (TAC) on cardiac function and hypertrophy in wild-type (WT, n=12), GSNOR-deficient (GSNOR, n=5) and GSNOR-transgenic (GSNOR-Tg, n=6) mice that overexpresses GSNOR restrictively in cardiomyocytes. Degree of LV hypertrophy and function was examined with serial echocardiography and postmortem examination 4 weeks after TAC. Before TAC, body weight, LV mass, and fractional shortening (FS) were similar in the three genotypes. TAC induced marked LV hypertrophy (LV mass; from 82±5 to 135±15mg, P
format Article
fullrecord <record><control><sourceid>wolterskluwer</sourceid><recordid>TN_cdi_wolterskluwer_health_00003017-201611111-03054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00003017-201611111-03054</sourcerecordid><originalsourceid>FETCH-wolterskluwer_health_00003017-201611111-030543</originalsourceid><addsrcrecordid>eNqdjs1KxDAUhYMoWH_e4b5AID_tlLqTzshsRBfuh5jemURDMtyklr69UXwCz-Zw4PvgXLBGdqrlbaeHS9YIIQbea6Wu2U3OH3VudN81bHl8z4WMLSAHJcUD7KIz0eIEW4y-UMprMMWnCM---JMpmGE0NHljYb-ekSpydiuYWI01H-dof-ntTD6eYHSUorfwSpjzTAgvX0ghmemOXR1NyHj_17esfdq9jXu-pFCQ8meYF6SDQxOKO9S7QgvZcyXkRv6E1921-p_aN7aNVgk</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload</title><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mori, Naohiro ; Kai, Shinichi ; Sips, Patrick ; Irie, Tomoya ; Ichinose, Fumito</creator><creatorcontrib>Mori, Naohiro ; Kai, Shinichi ; Sips, Patrick ; Irie, Tomoya ; Ichinose, Fumito</creatorcontrib><description><![CDATA[Protein S-nitrosylation (SNO) is a post-translational modification of protein thiol, which is a major effector mechanism of nitric oxide (NO) signaling. Level of protein SNO is controlled by S-nitrosoglutathione reductase (GSNOR). Recently, we showed that GSNOR mitigates intracellular calcium overload and LV remodeling and dysfunction induced by chronic β-adrenergic receptor (AR) stimulation. To further explore the role of protein SNO in LV remodeling and heart failure, we examined impact of chronic pressure overload induced by transverse aortic constriction (TAC) on cardiac function and hypertrophy in wild-type (WT, n=12), GSNOR-deficient (GSNOR, n=5) and GSNOR-transgenic (GSNOR-Tg, n=6) mice that overexpresses GSNOR restrictively in cardiomyocytes. Degree of LV hypertrophy and function was examined with serial echocardiography and postmortem examination 4 weeks after TAC. Before TAC, body weight, LV mass, and fractional shortening (FS) were similar in the three genotypes. TAC induced marked LV hypertrophy (LV mass; from 82±5 to 135±15mg, P<0.001) and dysfunction (FS; from 54±4 to 43±5%, P<0.001) in WT mice. GSNOR-deficiency markedly worsen LV hypertrophy (LV mass; from 84±6 to 177±15mg, P<0.001 vs before TAC and vs WT) and dysfunction (FS; from 51±2 to 21±6% in GSNOR, P<0.001 vs before TAC and WT). In contrast, GSNOR-overexpression prevented the TAC-induced increase of LV mass (from 81±8 to 95±13mg, P=NS vs before TAC, P<0.001 vs WT and GSNOR) and reduction of FS (from 51±3 to 45±4%, P=NS vs before TAC, P<0.001 vs GSNOR). In conclusion, GSNOR prevents cardiac hypertrophy and dysfunction during chronic pressure overload. These results indicate that the manipulation of protein SNO levels may prove therapeutic in cardiac remodeling and heart failure.]]></description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><language>eng</language><publisher>by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><ispartof>Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A19210-A19210</ispartof><rights>2016 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Mori, Naohiro</creatorcontrib><creatorcontrib>Kai, Shinichi</creatorcontrib><creatorcontrib>Sips, Patrick</creatorcontrib><creatorcontrib>Irie, Tomoya</creatorcontrib><creatorcontrib>Ichinose, Fumito</creatorcontrib><title>Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload</title><title>Circulation (New York, N.Y.)</title><description><![CDATA[Protein S-nitrosylation (SNO) is a post-translational modification of protein thiol, which is a major effector mechanism of nitric oxide (NO) signaling. Level of protein SNO is controlled by S-nitrosoglutathione reductase (GSNOR). Recently, we showed that GSNOR mitigates intracellular calcium overload and LV remodeling and dysfunction induced by chronic β-adrenergic receptor (AR) stimulation. To further explore the role of protein SNO in LV remodeling and heart failure, we examined impact of chronic pressure overload induced by transverse aortic constriction (TAC) on cardiac function and hypertrophy in wild-type (WT, n=12), GSNOR-deficient (GSNOR, n=5) and GSNOR-transgenic (GSNOR-Tg, n=6) mice that overexpresses GSNOR restrictively in cardiomyocytes. Degree of LV hypertrophy and function was examined with serial echocardiography and postmortem examination 4 weeks after TAC. Before TAC, body weight, LV mass, and fractional shortening (FS) were similar in the three genotypes. TAC induced marked LV hypertrophy (LV mass; from 82±5 to 135±15mg, P<0.001) and dysfunction (FS; from 54±4 to 43±5%, P<0.001) in WT mice. GSNOR-deficiency markedly worsen LV hypertrophy (LV mass; from 84±6 to 177±15mg, P<0.001 vs before TAC and vs WT) and dysfunction (FS; from 51±2 to 21±6% in GSNOR, P<0.001 vs before TAC and WT). In contrast, GSNOR-overexpression prevented the TAC-induced increase of LV mass (from 81±8 to 95±13mg, P=NS vs before TAC, P<0.001 vs WT and GSNOR) and reduction of FS (from 51±3 to 45±4%, P=NS vs before TAC, P<0.001 vs GSNOR). In conclusion, GSNOR prevents cardiac hypertrophy and dysfunction during chronic pressure overload. These results indicate that the manipulation of protein SNO levels may prove therapeutic in cardiac remodeling and heart failure.]]></description><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqdjs1KxDAUhYMoWH_e4b5AID_tlLqTzshsRBfuh5jemURDMtyklr69UXwCz-Zw4PvgXLBGdqrlbaeHS9YIIQbea6Wu2U3OH3VudN81bHl8z4WMLSAHJcUD7KIz0eIEW4y-UMprMMWnCM---JMpmGE0NHljYb-ekSpydiuYWI01H-dof-ntTD6eYHSUorfwSpjzTAgvX0ghmemOXR1NyHj_17esfdq9jXu-pFCQ8meYF6SDQxOKO9S7QgvZcyXkRv6E1921-p_aN7aNVgk</recordid><startdate>20161111</startdate><enddate>20161111</enddate><creator>Mori, Naohiro</creator><creator>Kai, Shinichi</creator><creator>Sips, Patrick</creator><creator>Irie, Tomoya</creator><creator>Ichinose, Fumito</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope/></search><sort><creationdate>20161111</creationdate><title>Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload</title><author>Mori, Naohiro ; Kai, Shinichi ; Sips, Patrick ; Irie, Tomoya ; Ichinose, Fumito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-wolterskluwer_health_00003017-201611111-030543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Mori, Naohiro</creatorcontrib><creatorcontrib>Kai, Shinichi</creatorcontrib><creatorcontrib>Sips, Patrick</creatorcontrib><creatorcontrib>Irie, Tomoya</creatorcontrib><creatorcontrib>Ichinose, Fumito</creatorcontrib><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mori, Naohiro</au><au>Kai, Shinichi</au><au>Sips, Patrick</au><au>Irie, Tomoya</au><au>Ichinose, Fumito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><date>2016-11-11</date><risdate>2016</risdate><volume>134</volume><issue>Suppl_1 Suppl 1</issue><spage>A19210</spage><epage>A19210</epage><pages>A19210-A19210</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract><![CDATA[Protein S-nitrosylation (SNO) is a post-translational modification of protein thiol, which is a major effector mechanism of nitric oxide (NO) signaling. Level of protein SNO is controlled by S-nitrosoglutathione reductase (GSNOR). Recently, we showed that GSNOR mitigates intracellular calcium overload and LV remodeling and dysfunction induced by chronic β-adrenergic receptor (AR) stimulation. To further explore the role of protein SNO in LV remodeling and heart failure, we examined impact of chronic pressure overload induced by transverse aortic constriction (TAC) on cardiac function and hypertrophy in wild-type (WT, n=12), GSNOR-deficient (GSNOR, n=5) and GSNOR-transgenic (GSNOR-Tg, n=6) mice that overexpresses GSNOR restrictively in cardiomyocytes. Degree of LV hypertrophy and function was examined with serial echocardiography and postmortem examination 4 weeks after TAC. Before TAC, body weight, LV mass, and fractional shortening (FS) were similar in the three genotypes. TAC induced marked LV hypertrophy (LV mass; from 82±5 to 135±15mg, P<0.001) and dysfunction (FS; from 54±4 to 43±5%, P<0.001) in WT mice. GSNOR-deficiency markedly worsen LV hypertrophy (LV mass; from 84±6 to 177±15mg, P<0.001 vs before TAC and vs WT) and dysfunction (FS; from 51±2 to 21±6% in GSNOR, P<0.001 vs before TAC and WT). In contrast, GSNOR-overexpression prevented the TAC-induced increase of LV mass (from 81±8 to 95±13mg, P=NS vs before TAC, P<0.001 vs WT and GSNOR) and reduction of FS (from 51±3 to 45±4%, P=NS vs before TAC, P<0.001 vs GSNOR). In conclusion, GSNOR prevents cardiac hypertrophy and dysfunction during chronic pressure overload. These results indicate that the manipulation of protein SNO levels may prove therapeutic in cardiac remodeling and heart failure.]]></abstract><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A19210-A19210
issn 0009-7322
1524-4539
language eng
recordid cdi_wolterskluwer_health_00003017-201611111-03054
source American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
title Abstract 19210: Enhanced Denitrosylation Mitigates Cardiac Hypertrophy and Dysfunction During Chronic Pressure Overload
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A28%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%2019210:%20Enhanced%20Denitrosylation%20Mitigates%20Cardiac%20Hypertrophy%20and%20Dysfunction%20During%20Chronic%20Pressure%20Overload&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Mori,%20Naohiro&rft.date=2016-11-11&rft.volume=134&rft.issue=Suppl_1%20Suppl%201&rft.spage=A19210&rft.epage=A19210&rft.pages=A19210-A19210&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/&rft_dat=%3Cwolterskluwer%3E00003017-201611111-03054%3C/wolterskluwer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true